US OptionsDetailed Quotes
AMRN240719C500
- 0.26
- -0.01-3.70%
15min DelayClose Jul 19 15:59 ET
0.28High0.26Low
0.28Open0.27Pre Close11 Volume29 Open Interest0.50Strike Price306.00Turnover5555.64%IV-3.06%PremiumJul 19, 2024Expiry Date0.28Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.8618Delta0.5053Gamma2.41Leverage Ratio-1.3294Theta0.0000Rho2.08Eff Leverage0.0000Vega
Amarin Stock Discussion
Sign in to post a comment
$Amarin(AMRN.US$ Reported Saturday, New REDUCE-IT Analyses By Amarin Show That VASCEPA/VAZKEPA Benefits High-Risk Cardiovascular Disease Patient Subgroups
$Amarin(AMRN.US$ Amarin Received Decision To Grant From European Patent Office For New Patent Covering VAZKEPA That Will Extend VAZKEPA Exclusivity Eight Additional Years Into 2039
$Amarin(AMRN.US$ Amarin Says Initiated Shareholder Approval Process To Execute Share Repurchase Program Of Up To $50M By End Of Q2 2024
1
$Amarin(AMRN.US$ Officer Holt Patrick purchased 14,426 shares of Common Stocks on Jan 22, 2024 at an average price of $1.09 for a total value of $15,724.34.![]()
2
1
$Amarin(AMRN.US$ Amarin Plans To Initiate Share Repurchase Program of Up to $50M
Moomoo 24/7· 1 min ago![]()
Moomoo 24/7· 1 min ago
2
Amarin's low P/S ratio is due to declining revenue and expectations of below-average growth. Lack of investor confidence in future revenue growth may further affect its share price if no improvements are made.
No comment yet
The Real WojakOP : Sold $0.81 thanks for the money